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Abstract
Background: Although the World Health Organization has recommended the diagnosis and prophylactic
treatment of latent tuberculous infection (LTBI) in child household contacts of tuberculosis (TB) cases, the national
programs in high-burden TB regions rarely implement adequate screening of this high-risk group, mainly because
of resource limitations. We aimed to evaluate the prevalence of LTBI among pediatric household contacts of TB
cases in two high-burden provinces in Iran.
Methods: We conducted a cohort study in children who had been in household contact with a TB index. All
subjects were assessed for active TB disease. For LTBI diagnosis, tuberculin skin test (TST) and QuantiFERON®-TB
Gold Plus (QFT-Plus) were performed at the time of the index TB case diagnosis, as well as, 3, 12, and 18 months, if
the first results were negative. In addition, interferon-γ-induced protein-10(IP-10) concentrations were measured for
all participants.
Results: A total of 230 children were enrolled, who had contact with an index TB case. Three contacts were
diagnosed with active TB. According to the TST/QFT-Plus results, 104 (45.2%) children were identified with LTBI
during our study. Significantly increased IP-10 levels were found in LTBI patients compared to healthy contacts.
Accordingly, more than 50% of LTBI contacts and about 10% of healthy contacts were considered as IP-10-positive.
Conclusion: This study alarmingly illustrates a high prevalence of LTBI among Iranian children exposed to TB cases.
We, therefore, emphasize that the children living in close contact with an infectious TB case should be screened
effectively and receive prophylactic therapy.
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Background
Tuberculosis (TB), disease caused by Mycobacterium tu-
berculosis (Mtb), is one of the most important causes of
childhood morbidity and mortality worldwide [1]. Glo-
bally, 1.1 million children under 15 years of age became
ill with TB disease in 2018, and there were 205,000
deaths due to TB, according to the World Health
Organization (WHO) reports [2]. Based on the global
estimation, the incidence of TB is reducing by ap-
proximately 1.5% annually, however, this reduction
will be insufficient for the elimination target set for
2050 proposed by the WHO [3]. This challenge could
be due to the under-reporting and under-diagnosis of
TB cases in many countries which has been estimated
to be around one-third of the cases [4, 5]. Accord-
ingly, to implement successful disease control strat-
egies, the WHO has recommended the need for not
only accurate diagnosis and treatment of active TB
subjects but also the early diagnosis and treatment of
latent tuberculous infection (LTBI) in the groups at
high risk of developing a severe infection, particularly
in the pediatric population [6, 7].
Children with LTBI do not show any symptoms of the
active disease but could develop disease in the near or
remote future, a process called TB reactivation [8].
Therefore, tracing and screening of pediatric household
contacts of TB cases has a huge potential to detect and
provide early treatment for children with TB and LTBI;
however, although it is generally recommended by the
WHO, it is infrequently practiced in resource-limited
countries [9]. Young children with LTBI are at higher
risk of developing active TB than adults, thus, it is of
public health importance to identify LTBI in this popula-
tion [10]. Moreover, in young children between 2 and 4
years of age, TB is often disseminated due to early,
hematogenous spread of the mycobacteria after primary
pulmonary infection and they have the highest risk of
progression to central nervous system TB [11]. Most
cases of progression to active TB disease among the
pediatric population occur within 12months of initial
infection [12].
The tuberculin skin test (TST) and interferon-γ release
assays (IGRA) are used for the screening of LTBI and
are based on stimulating the cell-mediated immune sys-
tem to detect whether it recognizes the antigens of Mtb
[13, 14]. However, both TST and IGRA have reduced
sensitivity in immunocompromised patients and cannot
discriminate between active TB and LTBI [15]. More-
over, inadequate and insufficient investigations have
been carried out in pediatric subjects, and these studies
suggest that the performance of these assays varies from
those obtained in adults, mainly in countries with a high
incidence of TB [16]. Consequently, the diagnosis of
LTBI should be qualified by the simultaneous use of
various tools and measurement of other biomarkers to
improve the sensitivity of the diagnosis. Based on these
assumptions, the QuantiFERON®-TB Gold Plus (QFT-
Plus), a new version of IGRAs, and the IFN-γ inducible
protein 10 (IP-10) assay have been recently evaluated in
the field of TB diagnosis [17, 18]. The QFT-Plus exploit
both CD4+ and CD8+ T cells immune response to Mtb,
having an important clinical value in conditions of im-
mune depression due to CD4 T-cell impairments as in
HIV-infection. In addition, a number of studies suggest
that the CD8+ response is present at the onset of the in-
fection and RD1-specific CD8 T-cells are more frequently
detected during active TB compared to LTBI and, within
LTBI, in recent infection compared with remote infection
[19, 20]. IP-10 has been found to be increased in the
plasma of TB patients and its advantage is that it is
expressed in high levels following Mtb antigen-specific
stimulation in both active TB and LTBI, suggesting its
potential as a biomarker for TB in children [21, 22].
Although screening and management of pediatric
household contacts of TB patients has great potential to
reduce TB-related morbidity and mortality in children,
the prevalence of LTBI cases among Iranian children has
not been evaluated and reported so far. Therefore,
the aim of the present study was to estimate the preva-
lence of LTBI among children exposed to TB cases and
determine the accuracy of the IP-10assays for detection
of children with LTBI.
Methods
Study design and population
This cohort study included a sample of children who
had been in household contact with a TB index case
within the previous 6 months. Case recruitment was
performed in the regional reference centers for TB in
Golestan and Sistan-Baluchestan provinces from July
2017 to August 2019.The list of adults with a history
of cough > 2 weeks who had a diagnosis of sputum
smear and/or culture-positive TB was provided. The
adults with confirmed TB were questioned about any
household contact with children under 18 years of
age. Those responding positively were asked to bring
the children to the selected health centers for evalu-
ation and were invited to participate in our study.
The study was undertaken at an out-patient level.
Ethics statement
This study was approved by the Ethical Committee of
Shahid Beheshti University of Medical Sciences, (ap-
proval number: IR.NIMAD.REC.1395.039). The patients
or legal guardians of the participants provided signed in-
formed consent forms for inclusion in the study.
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Radiological and microbiological evaluation
All child household contacts were clinically evaluated at
the following times: at the time of the index TB case
diagnosis, as well as, 3, 12, and 18 months, if the first re-
sults were negative. Chest X-ray was conducted in any
contact with symptoms or signs of active TB and the
clinical diagnosis of active pulmonary TB was made
using a combination of clinical and chest X-ray features.
All chest X-rays were examined by two pediatric pulmo-
nologists, blinded to clinical details, and a scale of severity
was determined as described by Petruccioli et al. They
were classified as: 0: normal chest X-rays; 1: mild grade; 2:
intermediate grade; 3: high grade [23]. Sputum/gastric lav-
age followed by smear examination and culture on Low-
enstein Jensen media were performed for those with
clinical/radiological features of pulmonary TB.
TST and QFT-plus assays
QFT-Plus and TST were performed at the four times, as
described above. The QFT-Plus assay was carried out ac-
cording to the manufacturer’s instructions (QIAGEN,
Germantown, MD, USA). Briefly, blood samples (4 ml)
were collected and drawn directly into four QFT-Plus
tubes (1 ml into each tube), TB1 tube containing the
Mtblong peptide antigens derived from ESAT-6 and
CFP-10 stimulating a cell-mediated immune response
from CD4 T-cells; TB2tube with shorter peptides indu-
cing CD8 T-cells in addition to the same antigens of
TB1,Mitogen tube with non-specific mitogen phytohem-
agglutinin (PHA) to be used as the positive control and
Nil (blank) tube to be used as the negative control. The
three tubes were incubated at 37° for 16–24 h. Super-
natant plasma was harvested from the tubes after centri-
fugation and was stored at − 80 °C. IFN-γ was measured
u s i n g a QFT -P l u s Ana l y s i s S o f tw a r e (www .
quantiFERON.com) in a Bio-Rad (Hemel Hempstead,
UK) plate reader (model 550) at 450 nm. The results
were interpreted as negative, indeterminate, or positive
using the manufacturer’s software. QFT tests were
regarded as positive if the antigen-stimulated response
of IFN- γ (TBAg-Nil) was 0.35 IU/ml or more, or nega-
tive if the mitogen stimulated response (Mitogen-Nil)
was 0.5 IU/ml and the antigen-stimulated response was
less than 0.35 IU/ml, or indeterminate if both mitogen-
stimulated and antigen-stimulated responses were, 0.35
IU/ml and un-stimulated response (Nil) 0.8 IU/ml.
After QFT-Plus blood sampling, the two-step TST was
performed by trained personnel following standard
procedures. Accordingly, all participants were admin-
istered the TST via intradermal injection of 5 U of
purified protein derivative (PPD) and indurations were
measured using the palpation method 48–72 h later.
TST results interpreted as positive (≥10 mm) and
negative (< 10 mm).
LTBI was defined as the presence of a positive QFT-
Plus result and/or positive TST result together with the
absence of clinical signs/radiological evidence of active
TB disease. In addition, in our study, the contacts with-
out clinical and radiological evidence that were negative
for both QFT-Plus and TST were considered as healthy
contacts.
IP-10 assay
IP-10 concentrations were measured in QFT-Plus super-
natants using a Human IP10 ELISA Construction Kit
(Antigenix America Inc., New York, NY) and classified
as positive or negative according to a receiver operating
curve as previously described by Yassin et al. [24].
Statistical analysis
Data analysis was performed using SPSS v.22 (IBM
Corp, New York, USA) and Prism 7 software (Graphpad
Software 6.0, San Diego, USA). The ability of IP-10 to
discriminate between children with and without TB in-
fections was evaluated using Receiver Operating Charac-
teristic (ROC) curves. ROC curves were constructed
with LTBI contacts and healthy contacts. The significant
area under curve (AUC) for LTBI and healthy contacts
was compared to determine whether IP10 could distin-
guish between the two conditions. The Kruskall-Wallis
and Mann-Whitney U tests were used for comparisons
and a Bonferroni correction was applied. Statistical tests
were considered significant if P values < 0.05.
Results
Study population
A total of 230 TB-exposed children were enrolled. Of
these, 76 (33%) had been exposed in the last 6 months
(e.g. retrospective cases) and 154 (67%) children were re-
cruited prospectively as new index cases were diagnosed.
All the children enrolled had received the BCG vaccine
in the first 2 months of life. Of the 230 children re-
cruited, 52.1% were male and 47.9% were female. More-
over, the median age of the participants was 8.5 (range
1–17) years, and 4.8% were less than 24months of age.
Demographic characteristics and symptoms identified at
the time of screening are shown in Table 1. Through
clinical and microbiological evaluation, one household
contact was diagnosed with active TB at baseline, one
child 12 months after the diagnosis of the index case,
and another 18 months after the diagnosis of the index
case. Accordingly, 227 children (98.7%) remained
asymptomatic.
TST and QFT-plus results
Our findings revealed that a total of 36% (80/230) of
child TB contacts were TST positive at both baseline
and follow-up. Exhaustively, 12.6% (29/230) of the
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evaluated contacts showed positive TST at baseline.
Among contacts with negative baseline TST results,8%
(16/201), 13.5% (29/185), and 8.3% (13/156) had become
positive after 3, 12, and 18 months, respectively.
QFT-Plus results indicated that 20.9% (48/230) of
child contacts showed positive IFN-γ responses at the
baseline. Moreover, among the contacts with baseline
QFT-Plus-negative results and valid follow-up QFT-Plus
data, 13.7% (25/182), 6.4% (10/157), and 2.7 (4/147),
showed an increase over the baseline IFN-γ value after
3, 12, and 18 months, respectively.
According to the TST/QFT-Plus results and the ab-
sence of clinical signs/radiological evidence of active
TB, 45.2% (104/230) of children were identified as
LTBI at the end of this study. Our findings revealed
that 28.3% (65/230) of the household pediatric con-
tacts were considered as LTBI at the baseline, while,
the rate of LTBI conversion was 17% (39/230). Ex-
haustively, 2.3% (12/165), 14.4% (22/153), and 2.3%
(5/131) of contacts were identified as LTBI after 3,
12, and 18 months, respectively. Table 2 shows the
TST and QFT-Plus results among pediatric household
contacts of TB cases.
IP-10 results
Significantly increased IP-10 levels were found in LTBI
patients (Mean ± standard error of the mean [SEM]:
2134 ± 362.5 for TB1 and 2379 ± 408.5 for TB2) com-
pared to healthy contacts (TST−/QFT-) (Mean ± SEM:
208.6 ± 90.58 for TB1 and 158.4 ± 72.56 for TB2) in re-
sponse to both TB1 and TB2 stimulation (Fig. 1). To de-
fine IP-10 results as positive or negative, a cut-off value
for IP-10 was calculated using the ROC curve. For TB1
a cut-off of 67.2 pg/mL identifies LTBI with 60.2% sensi-
tivity (50.5–69.1%) and 90% specificity (83.12–94.38%);
similarly, for TB2, an IP-10 level > 142.3 pg/mL predicted
LTBI with 53.4% sensitivity (43.8–62.7%) and 93.7% spe-
cificity (87.5–96.9%). Accordingly, 59.6% (62/104) of
LTBI contacts and 11.3% (14/123) of healthy contacts
were considered as IP-10-TB1-positive, respectively. In
addition, the proportion of LTBI and healthy children
with positive IP-10-TB2 was, respectively, 53.8% (56/104)
and 8.9% (11/123).
Discussion
Recognizing children with active TB or LTBI and either
treating disease or targeting prophylaxis to high-risk
groups are strategies recommended by the WHO in
high TB burden regions. However, the identification
of LTBI cases is more challenging in low–middle-in-
come countries [25, 26].
To the best of our knowledge, this study is the most
comprehensive investigation on the prevalence of LTBI
among household child TB contacts in Iran. Our find-
ings revealed that the prevalence and incidence of LTBI
among Iranian children exposed to an index TB case
with sputum smear and/or culture-positive adults
were28.3 and 17%, respectively. These children are at
high risk of developing active TB which is very worrying.
Our findings are similar to other investigations in which
only under half of child household contacts have evi-
dence of LTBI [27, 28]. The high prevalence of LTBI
found in our study supports that children are very sus-
ceptible to exposure to an active TB case and are at a
high risk of LTBI [28]. Moreover, we detected three pa-
tients with active TB, in which two cases did not have
clinical evidence of active disease at the beginning of the
screening, thus were considered as incident cases. How-
ever, we cannot claim conclusively that the source of the
infection in this population was the index case.
A meta-analysis including 95 studies from low- and
middle-income settings estimated the prevalence of
LTBI among household contacts to be 51.5% (95% CI
47.1–55.8%, I (2)=98.9%), with the highest incidence
among children between 5 and 14 years of age [28]. In
another study in Laos, Nguyen et al. reported that the
prevalence of LTBI among child household contacts was
31.1% and increased with age from 26.0% in children
Table 1 Demographic and clinical characteristics of the Iranian
pediatric household contacts of TB cases
Demographic and clinical characteristics N (%)
Adult tuberculosis source cases (N = 64)
Sputum smear(+)/culture (+) 57 (89.1)
Sputum smear(−)/culture(+) 7 (10.9)




Age < 2 years 11 (4.8)
Age 2–5 years 38 (16.5)
Age 5–10 years 76 (33.1)
Age ≥ 10 years 105 (45.6)
Tuberculosis prophylaxis at the evaluation 11 (4.8)
Isoniazid preventive chemotherapy 7 (3)
Rifampin preventive chemotherapy 1 (0.4)
Ethambutol preventive chemotherapy 1 (0.4)
Pyrazinamide preventive chemotherapy 1 (0.4)
Other TB preventive chemotherapy 1 (0.4)
Symptoms at entry to the study
Cough 5 (2.2)
Sputum 5 (2.2)
Weight loss 2 (0.9)
Fever 1 (0.4)
Chest pain 3 (1.3)
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below 5 years to 35.7% in children between 6 and 15
years [29]. So far, there is only limited data available on
prevalence of LTBI among household contacts of TB
cases in Iran. Previously, Shamaei et al. reported that
27.5% of close-family contacts of hospitalized TB pa-
tients in Iran were diagnosed with LTBI [30]. Therefore,
our data reinforce the crucial importance of systematic
screening and close follow-up of child household con-
tacts, as well as a precise targeting of preventive treat-
ment in this population.
TST is used as the only screening method to identify
LTBI children in several high burden TB countries with
limited resources, but the low sensitivity of TST, its poor
specificity due to cross-reactions with environmental
non-tuberculous mycobacteria and the BCG vaccine, as
well as its unreliability in children with immunosuppres-
sion and malnutrition could limit the applicability of this
approach [31, 32]. On the other hand, although IGRAs
have emerged as promising alternatives to the TST, the
limitations of these tests are gradually becoming appar-
ent with their widespread use [33, 34]. For instance, pre-
vious surveys in both high and low TB burden regions
confirmed that IGRA conversions and reversions could
occur and there is some confusion about how to inter-
pret such results [35–37]. Accordingly, several national
guidelines (e.g. UK, Canada, Germany, the Netherlands,
Italy, Switzerland, Norway, Spain, Ireland, and Korea)
recommend a two-step approach of TST first, followed
by an IGRA [33]. In the current study, we used both
TST and IGRA assay to investigate LTBI cases among
close contacts to an index TB case. In addition, we
rechecked TST or IGRA in the subjects after 3, 12, and
18months when the primary result was negative. Our
findings indicated that there was adisagreement between
TST and QFT-plus results. For contacts in whom TST
and QFT-plus results were discordant, it is impossible to
know which test was correct because there is no refer-
ence standard. In our study, BCG vaccination status
might affect TST positivity in adjusted multivariable
analysis. The quality of BCG vaccination among contacts
and the percentage of subjects with booster vaccinations
could contribute to the different degrees of concordance
between TST and QFT-plus results. Moreover, although
TST was performed by trained personnel following
standard procedures, the disagreement between TST
and QFT-plus results could be due to the variability in
reading TST in the pediatric population. Some authors
previously reported that the disagreement rate between
TST and IGRA tests was about 10%, regardless of BCG
vaccination [38, 39].
Table 2 TST and QFT-Plus results in Iranian pediatric household contacts of TB cases
TST+/QFT- TST−/QFT+ TST+/QFT+ TST−/QFT-
At initiation of screening (n = 230) 18 (7.8%) 37 (16%) 11 (4.8%) 164 (71.3%)
3 months after the diagnosis of index (n = 164) 4 (2.4%) 14 (8.5%) 5 (3.1%) 141 (86%)
12 months after the diagnosis of index (n = 141) 16 (11.3%) 9 (6.4%) 1 (0.7%) 115 (81.5%)
18 months after the diagnosis of index (n = 115) 11 (9.6%) 3 (2.6) 1 (0.9%) 90 (85.8%)
Footnotes: QFT-plus QuantiFERON®-TB Gold Plus, TB tuberculosis, TST tuberculin skin test
Fig. 1 Significantly increased IP-10 levels in LTBI patients compared to healthy contacts. A) IP-10 levels in response toTB1 and B) TB2 stimulation.
ELISA was carried out with QFT-Plus supernatants and IP-10 was expressed as pg/mL. The horizontal lines represent the median; statistical analysis
was performed using the Mann-Whitney test with Bonferroni correction and **** represents P-value < 0.0001. Footnotes: IP-10: IFN-γ inducible
protein10; LTBI: latent tuberculosis infection
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In the present study, we also evaluated the accuracy of
IP-10 assay in the plasma of QFT-Plus for the diagnosis of
LTBI among Iranian household pediatric contacts of TB
cases. The results of some investigations suggest that IP-
10 assay could be an alternative to IGRA, may be useful
for diagnosing LTBI cases as it would be easier to use [18,
40]. Our findings indicated that IP-10 levels are signifi-
cantly increased in contacts with LTBI compared to
healthy contacts in response to both TB1 and TB2 anti-
gens (P value < 0.0001). Considering the IP-10 results, no
significant differences were observed between the TB1
and TB2. Therefore, the IP-10-based assay showed a high
discriminating power and could help to distinguish be-
tween child contacts with LTBI from healthy contacts. In
addition, a high concordance between the IP-10 assay and
TST and QFT-plus tests was found.
IP-10 assay was previously thought to have significant
advantages over IGRAs, including the possibility to use
smaller blood volumes and to be detected in urine sam-
ples. It is also possible to measure IP-10 in dried plasma
spots in filter papers allowing cheap and simple mail
transportation at room temperature [18, 21, 41, 42].
Therefore, IP-10 assay would be useful as an uncompli-
cated and inexpensive alternative test for LTBI diagnosis
in child household contacts of TB cases, especially in
low-resource settings. Although in our studyIP-10 assay
showed an acceptable specificity (90% for TB1 and
93.7% for TB2), it had a low sensitivity (60.2% for TB1
and 53.4% for TB2) for LTBI diagnosis. Importantly, it
should be noted that the combination of the IGRAs and
IP-10 assay has been reported to increase sensitivity
[18]. Moreover, early studies suggest that the IP-10-
based assay could not help to discriminate between
active TB and LTBI among children [43].
The advantage of this study is that we used various ap-
proach for identification of LTBI among child household
contacts, including TST, QFT, and IP-10 assay. Hence,
our methodology allowed calculation of the prevalence
of LTBI among child household contacts which, so far,
has not been performed since LTBI cannot easily be
demonstrated using a single method. However, some
limitations could be noted in our study. For instance, in-
vestigator bias was further limited by the fact that TST
could be interpreted differently by independent experts.
Moreover, in this survey, some participants enrolled into
the study retrospectively and others prospectively, which
decreases the power of the study. Finally, in this investi-
gation TST was performed by more than one investiga-
tor. Therefore, it might be cause pre-observer bias,
which is difficult to objectively evaluate TST results.
Conclusion
The results of this study alarmingly illustrate a high
prevalence of LTBI among Iranian children exposed to
an index TB case. Our experience, therefore, emphasizes
that young children living in close contact with a source
of TB should receive TB preventive therapy. In addition,
establishing a national screening programme and incorp-
orating various methods for LTBI identification among
child household contacts should be taken into account
in the design of TB control strategies in Iran. Import-
antly, the identification and prophylactic treatment of
LTBI cases is crucial to the control and prevention of
pediatric TB and requires more and greater efforts to
this end. Moreover, the results of our study, if validated
in further large-scale cohort studies, suggested that
IP-10 assay could be an alternative biomarker for de-
tection of Mtb infection and might provide some ad-
vantages over QFT and TST as the point-of-care test
implementation.
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